Longevity of naturally-acquired antibody response to Plasmodium Vivax merozoite surface protein 1 paralog vaccine candidate
Issued Date
2018
Copyright Date
2018
Resource Type
Language
eng
File Type
application/pdf
No. of Pages/File Size
xiv, 126 leaves : ill. (some col.)
Access Rights
open access
Rights
ผลงานนี้เป็นลิขสิทธิ์ของมหาวิทยาลัยมหิดล ขอสงวนไว้สำหรับเพื่อการศึกษาเท่านั้น ต้องอ้างอิงแหล่งที่มา ห้ามดัดแปลงเนื้อหา และห้ามนำไปใช้เพื่อการค้า
Rights Holder(s)
Mahidol University
Bibliographic Citation
Thesis (M.Sc. (Medical Technology))--Mahidol University, 2017
Suggested Citation
Hay, Man Kyaw Min, 1991- Longevity of naturally-acquired antibody response to Plasmodium Vivax merozoite surface protein 1 paralog vaccine candidate. Thesis (M.Sc. (Medical Technology))--Mahidol University, 2017. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/92279
Title
Longevity of naturally-acquired antibody response to Plasmodium Vivax merozoite surface protein 1 paralog vaccine candidate
Author(s)
Abstract
Plasmodium vivax merozoite surface protein 1 paralog (PvMSP1P) is a glycosylphosphatidylinositol anchored blood-stage protein expressed on merozoite surface. It is proposed as a blood-stage vaccine candidate against P. vivax because of its ability to induce immune responses on natural P. vivax exposure and in immunized animal. Here, cross-sectional survey and longitudinal study were conducted for monitoring the longevity of antibody and memory B cell responses to PvMSP1P during and after infection with P. vivax. The antibody titer and neutralizing antibodies against PvMSP1P-erythrocyte binding were demonstrated by using enzyme-linked immunosorbent assay (ELISA) and in vitro erythrocyte inhibition binding assay (EIBA) respectively. In addition, memory B cell response to PvMSP1P was also performed using flow cytometric analysis and enzyme-linked immunospot (ELISPOT) assay. The seroprevalence of anti-PvMSP1P response was significantly higher in acutely infected P. vivax patients, 73% of total 40 individuals had a seropositive response to this antigen. The positive anti-PvMSP1P response was maintained up to 9 months post-infection. The high responder group from PvMSP1P-seropositive patients strongly inhibited the binding to erythrocytes and some individuals had a stable anti-PvMSP1P neutralizing antibody for at least 12 months post-infection. Interestingly, this persistence of antibody response was associated with the presence of PvMSP1P-specific memory B cells and the maintenance of circulating CD19+CD10-CD27+ cells at post-infection. Altogether, PvMSP1P antigen has immunogenicity in induction of antibody response and memory B cell development during infection which could be maintained after recovered from infection. Therefore, PvMSP1P antigen should also be considered as a reliable vaccine candidate for blood-stage P. vivax
Description
Medical Technology (Mahidol University 2017)
Degree Name
Master of Science
Degree Level
Master's degree
Degree Department
Faculty of Medical Technology
Degree Discipline
Medical Technology
Degree Grantor(s)
Mahidol University